skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Three major deals in the second half of July(Source:Alamy)

Three Chinese bioventures completed financing activities in the second half of July, raising roughly $175m combined.

TransThera Biosciences Co. Ltd. raised roughly $100m in a Series D venture capital round announced on 23 July and co-led by China's CITIC Private Equity Funds Management and China Structural Reform Fund. TransThera will use the proceeds to further develop its small molecule assets in an international setting, the biotech said.

The Nanjing-based venture gained attention in 2020 when it out-licensed non-alcoholic steatohepatitis candidate TT-01025 to South Korea's LG Chem, Ltd., in a deal worth up to $350m including upfront cash and milestone payments. (Asia Deal Watch Takeda Will Employ Engitixs ECM Tech In Liver Fibrosis Indications)

TransThera forged a partnership in May with Roche Holding AG to study combining its spectrum-selective kinase inhibitor TT-00420 with the Swiss giant’s anti-PD-L1 antibody Tecentriq (atezolizumab) for the treatment of patients with gastrointestinal tract cancers in China.

Another domestic cancer drug developer, Guangzhou Lupeng Pharmaceutical Co. Ltd., raised $35m in a pre-Series B round led by Singapore's Temasek, the company said on 28 July.

The proceeds will fund Lupeng's clinical development of selective BCL-2 inhibitor LP-108 and other drug candidates and came in the wake of a CNY170m ($26m) Series A-plus round in June 2020.

Lupeng was co-founded by Fenlai Tan and Yi Chen in June 2018; Tan was previously senior vice president and chief medical officer at China's Betta Pharmaceuticals Co., Ltd.

Neukio Finances Cell Therapies

Meanwhile, newly established Neukio Biotherapeutics raised $40m from angel investors, the start-up said on 29 July. It plans to use the proceeds to set up a research and development facility devoted to allogenic, off-the-shelf induced pluripotent stem cell (iPSC)-based chimeric antigen receptor natural killer cell (CAR-NK) technology platforms and therapies.

Lilly Asia Ventures led the financing with the participation of IDG Capital and Sherpa Investments.

At the helm of the biotech is Richard Wang, who previously served as founding CEO of Fosun Kite Biotechnology Co Ltd, a joint venture between China's Fosun Pharma and Kite Pharma.

Fosun Kite recently became the first company to secure regulatory approval for a CAR-T cell therapy in China, Yescarta (axicabtagene ciloleucel). (Fosun Kite Bags First China CAR-T Green Light)

According to Neukio, iPSC-CAR-NK is the latest development in cell therapy technology, for which it sees potential for scale-up production as an allogeneic universal product.

 

Read also

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: